Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent

Lars Jakobsen; Evald H Christiansen; Phillip Freeman; Johnny Kahlert; Karsten Veien; Michael Maeng; Bent Raungaard; Julia Ellert; Steen D Kristensen; Martin K Christensen; Christian J Terkelsen; Troels Thim; Ashkan Eftekhari; Rebekka V Jensen; Nicolaj B Støttrup; Anders Junker; Henrik S Hansen; Lisette O Jensen

doi:10.1002/ccd.30480

Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent

Lars Jakobsen^*, Evald H Christiansen, Phillip Freeman, Johnny Kahlert, Karsten Veien, Michael Maeng, Bent Raungaard, Julia Ellert, Steen D Kristensen, Martin K Christensen, Christian J Terkelsen, Troels Thim, Ashkan Eftekhari, Rebekka V Jensen, Nicolaj B Støttrup, Anders Junker, Henrik S Hansen, Lisette O Jensen

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Abstract

OBJECTIVES: To compare the efficacy and safety of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (O-SES) in patients with and without acute coronary syndrome (ACS) included in the SORT OUT X study.

BACKGROUND: The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with ACS when compared to patients without ACS. Whether the results from the SORT OUT X study apply to patients with and without ACS remains unknown.

METHODS: In total, 3146 patients were randomized to stent implantation with DTS (n = 1578; ACS: n = 856) or O-SES (n = 1568; ACS: n = 854). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.

RESULTS: At 1 year, the rate of TLF was higher in the DTS group compared to the O-SES group, both among patients with ACS (6.7% vs. 4.1%; incidence rate ratio: 1.65 [95% confidence interval, CI: 1.08-2.52]) and without ACS (6.0% vs. 3.2%; incidence rate ratio: 1.88 [95% CI: 1.13-3.14]). The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without ACS CONCLUSION: Compared to the O-SES, the DTS was associated with a higher risk of TLF at 12 months in patients with and without ACS. The differences were mainly explained by higher rates of TLR.

Originalsprog	Engelsk
Tidsskrift	Catheterization and Cardiovascular Interventions
Vol/bind	101
Nummer	1
Sider (fra-til)	13-21
Antal sider	9
ISSN	1522-1946
DOI	https://doi.org/10.1002/ccd.30480
Status	Udgivet - jan. 2023

Adgang til dokumentet

10.1002/ccd.30480Licens: CC BY-NC-ND

Citationsformater

Jakobsen, L., Christiansen, E. H., Freeman, P., Kahlert, J., Veien, K., Maeng, M., Raungaard, B., Ellert, J., Kristensen, S. D., Christensen, M. K., Terkelsen, C. J., Thim, T., Eftekhari, A., Jensen, R. V., Støttrup, N. B., Junker, A., Hansen, H. S., & Jensen, L. O. (2023). Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent. Catheterization and Cardiovascular Interventions, 101(1), 13-21. https://doi.org/10.1002/ccd.30480

@article{f41888cf79e549c09b194854f821239d,

title = "Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent",

abstract = "OBJECTIVES: To compare the efficacy and safety of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (O-SES) in patients with and without acute coronary syndrome (ACS) included in the SORT OUT X study.BACKGROUND: The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with ACS when compared to patients without ACS. Whether the results from the SORT OUT X study apply to patients with and without ACS remains unknown.METHODS: In total, 3146 patients were randomized to stent implantation with DTS (n = 1578; ACS: n = 856) or O-SES (n = 1568; ACS: n = 854). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.RESULTS: At 1 year, the rate of TLF was higher in the DTS group compared to the O-SES group, both among patients with ACS (6.7% vs. 4.1%; incidence rate ratio: 1.65 [95% confidence interval, CI: 1.08-2.52]) and without ACS (6.0% vs. 3.2%; incidence rate ratio: 1.88 [95% CI: 1.13-3.14]). The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without ACS CONCLUSION: Compared to the O-SES, the DTS was associated with a higher risk of TLF at 12 months in patients with and without ACS. The differences were mainly explained by higher rates of TLR.",

keywords = "acute coronary syndrome, randomized controlled trial, stent comparison, target lesion failure, Percutaneous Coronary Intervention/adverse effects, Sirolimus/adverse effects, Coronary Artery Disease/therapy, Humans, Risk Factors, Drug-Eluting Stents/adverse effects, Treatment Outcome, Prosthesis Design, Absorbable Implants, Myocardial Infarction/etiology, Time Factors, Cardiovascular Agents/adverse effects, Acute Coronary Syndrome/diagnostic imaging",

author = "Lars Jakobsen and Christiansen, {Evald H} and Phillip Freeman and Johnny Kahlert and Karsten Veien and Michael Maeng and Bent Raungaard and Julia Ellert and Kristensen, {Steen D} and Christensen, {Martin K} and Terkelsen, {Christian J} and Troels Thim and Ashkan Eftekhari and Jensen, {Rebekka V} and St{\o}ttrup, {Nicolaj B} and Anders Junker and Hansen, {Henrik S} and Jensen, {Lisette O}",

note = "{\textcopyright} 2022 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.",

year = "2023",

month = jan,

doi = "10.1002/ccd.30480",

language = "English",

volume = "101",

pages = "13--21",

journal = "Catheterization and Cardiovascular Interventions",

issn = "1522-1946",

publisher = "JohnWiley & Sons, Inc.",

number = "1",

}

Jakobsen, L , Christiansen, EH, Freeman, P, Kahlert, J, Veien, K, Maeng, M, Raungaard, B, Ellert, J, Kristensen, SD, Christensen, MK, Terkelsen, CJ , Thim, T, Eftekhari, A, Jensen, RV , Støttrup, NB, Junker, A, Hansen, HS & Jensen, LO 2023, 'Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent', Catheterization and Cardiovascular Interventions, bind 101, nr. 1, s. 13-21. https://doi.org/10.1002/ccd.30480

Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent. / Jakobsen, Lars ; Christiansen, Evald H; Freeman, Phillip et al.
I: Catheterization and Cardiovascular Interventions, Bind 101, Nr. 1, 01.2023, s. 13-21.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent

AU - Jakobsen, Lars

AU - Christiansen, Evald H

AU - Freeman, Phillip

AU - Kahlert, Johnny

AU - Veien, Karsten

AU - Maeng, Michael

AU - Raungaard, Bent

AU - Ellert, Julia

AU - Kristensen, Steen D

AU - Christensen, Martin K

AU - Terkelsen, Christian J

AU - Thim, Troels

AU - Eftekhari, Ashkan

AU - Jensen, Rebekka V

AU - Støttrup, Nicolaj B

AU - Junker, Anders

AU - Hansen, Henrik S

AU - Jensen, Lisette O

PY - 2023/1

Y1 - 2023/1

N2 - OBJECTIVES: To compare the efficacy and safety of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (O-SES) in patients with and without acute coronary syndrome (ACS) included in the SORT OUT X study.BACKGROUND: The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with ACS when compared to patients without ACS. Whether the results from the SORT OUT X study apply to patients with and without ACS remains unknown.METHODS: In total, 3146 patients were randomized to stent implantation with DTS (n = 1578; ACS: n = 856) or O-SES (n = 1568; ACS: n = 854). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.RESULTS: At 1 year, the rate of TLF was higher in the DTS group compared to the O-SES group, both among patients with ACS (6.7% vs. 4.1%; incidence rate ratio: 1.65 [95% confidence interval, CI: 1.08-2.52]) and without ACS (6.0% vs. 3.2%; incidence rate ratio: 1.88 [95% CI: 1.13-3.14]). The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without ACS CONCLUSION: Compared to the O-SES, the DTS was associated with a higher risk of TLF at 12 months in patients with and without ACS. The differences were mainly explained by higher rates of TLR.

AB - OBJECTIVES: To compare the efficacy and safety of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (O-SES) in patients with and without acute coronary syndrome (ACS) included in the SORT OUT X study.BACKGROUND: The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with ACS when compared to patients without ACS. Whether the results from the SORT OUT X study apply to patients with and without ACS remains unknown.METHODS: In total, 3146 patients were randomized to stent implantation with DTS (n = 1578; ACS: n = 856) or O-SES (n = 1568; ACS: n = 854). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.RESULTS: At 1 year, the rate of TLF was higher in the DTS group compared to the O-SES group, both among patients with ACS (6.7% vs. 4.1%; incidence rate ratio: 1.65 [95% confidence interval, CI: 1.08-2.52]) and without ACS (6.0% vs. 3.2%; incidence rate ratio: 1.88 [95% CI: 1.13-3.14]). The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without ACS CONCLUSION: Compared to the O-SES, the DTS was associated with a higher risk of TLF at 12 months in patients with and without ACS. The differences were mainly explained by higher rates of TLR.

KW - acute coronary syndrome

KW - randomized controlled trial

KW - stent comparison

KW - target lesion failure

KW - Percutaneous Coronary Intervention/adverse effects

KW - Sirolimus/adverse effects

KW - Coronary Artery Disease/therapy

KW - Humans

KW - Risk Factors

KW - Drug-Eluting Stents/adverse effects

KW - Treatment Outcome

KW - Prosthesis Design

KW - Absorbable Implants

KW - Myocardial Infarction/etiology

KW - Time Factors

KW - Cardiovascular Agents/adverse effects

KW - Acute Coronary Syndrome/diagnostic imaging

U2 - 10.1002/ccd.30480

DO - 10.1002/ccd.30480

M3 - Journal article

C2 - 36378691

SN - 1522-1946

VL - 101

SP - 13

EP - 21

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

IS - 1

ER -

Jakobsen L , Christiansen EH, Freeman P, Kahlert J, Veien K, Maeng M et al. Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent. Catheterization and Cardiovascular Interventions. 2023 jan.;101(1):13-21. Epub 2022 nov. 15. doi: 10.1002/ccd.30480

Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater